An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States.
VERDICT
The label
Accumulation
read at $4.56
Arbutus Biopharma Corporation holds its Accumulation at $4.56.
PHPhase · the trend structure carries the Accumulation label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-19
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 2 days
Price
$4.56
Valuation
5.49 trailing · -27.59 forward price to earnings
Values screen
PASS· score 95.7
Beta
0.62
SCREEN
The values screen, explained · five checks, plain English
Full pass across all five screens. This security clears the Titan Ethical Standard — its business and its balance sheet both stay inside the lines.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 0.5% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashCash held in interest-bearing accounts and securities is 10.8% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 0.0% of assets, under the 49% limit.Pass
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Five checks adapted from AAOIFI screening standards — business activity plus four balance-sheet ratios. All five must pass for ethical clearance.
OPPORTUNITY
The opportunity · what the numbers say it is worth
Our framework reads OPPORTUNITY — it trades at roughly a 14% discount to our $5.19 fair value, 10,054.50% revenue growth.
Read at
$4.56
5.49 P/E · -27.59 fwd
Our fair value
$5.19
14% discount
Analyst target (avg)
$5.19
+14% to current
Target low $4.87Analyst target rangeTarget high $5.51
▲ current $4.56 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$4.56
you are here
Conservative
$4.87
+7%
Analyst avg
$5.19
+14%
Our fair value
$5.19
+14%
Analyst high
$5.51
+21%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
10,054.50%
Profit margin
83.95%
Debt to equity
1.50
Analyst consensus
Strong Buy · 2 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
PLAIN
The business, in plain words · what the numbers mean
Small biotech takes aim at stubborn hepatitis B
Imagine a lab team building RNA tools to silence a virus that hides in liver cells for decades. Arbutus stands out because revenue has leapt more than ten thousand percent while margins sit at 84 percent and return on equity reaches 95 percent. The shares trade 14 percent below our fair value estimate with a strong buy consensus from the two analysts covering the name.
Those headline figures reflect a clean ethical screen and a clinical pipeline focused on chronic hepatitis B, where existing treatments still fall short. Forward earnings sit negative yet the balance sheet and growth trajectory point to real optionality if trials advance.
Clinical stage work always carries binary risk around trial data and funding needs, so any setback could erase the current margin of safety quickly. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
PEERS
Related securities · others in ABUS's space worth a look
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
ABUS trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.3% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (3 analysts) rates it strong buy, with a mean price target of $5. Entered 2026-07-20 · Accumulation
JOURNAL
The dated journal · newest first, never edited
2026-07-20Accumulation$4.56+7.3%Entry 5
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.3% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (3 analysts) rates it strong buy, with a mean price target of $5.
2026-07-18Accumulation$4.25+0.0%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (3 analysts) rates it strong buy, with a mean price target of $5.
2026-07-16Accumulation$4.25+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (96). The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (3 analysts) rates it strong buy, with a mean price target of $5.
2026-07-03Accumulation$4.25+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (96). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Accumulation$4.25Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with near-perfect ethical score (96). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
